Trials / Recruiting
RecruitingNCT04774419
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Intensity modulated radiation therapy (IMRT) | To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks. |
| DRUG | Dostarlimab | IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab. |
| RADIATION | Hypofractionated IMRT | Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week. |
Timeline
- Start date
- 2021-04-02
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2021-03-01
- Last updated
- 2026-02-03
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04774419. Inclusion in this directory is not an endorsement.